Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Outcome with Lenalidomide Plus Dexamethasone Followed By Early Autologous Stem Cell Transplantation in the ECOG-ACRIN E4A03 Randomized Clinical Trial: Long-Term Follow-up

Noa Biran, MD, Susanna Jacobus, David Siegel, MD PhD, Natalie Scott Callander, MD, Rafael Fonseca, MD, David H. Vesole, MD, Michael E. Williams, MD, Rafat Abonour, MD, Michael S Katz, BS,MBA, S. Vincent Rajkumar, Philip R. Greipp, MD

Blood (2015) 126 (23): 3174.

https://doi.org/10.1182/blood.V126.23.3174.3174

Published: 2015

Journal Articles

Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma

A. Keith Stewart, Susanna Jacobus, Rafael Fonseca, Matthias Weiss, Natalie S. Callander, Asher A. Chanan-Khan, S. Vincent Rajkumar

Blood (2015) 126 (11): 1294–1301.

https://doi.org/10.1182/blood-2014-12-613927

Published: 2015

Includes: Supplemental data

Journal Articles

Phase II Trial Of Initial Safety and Toxicity Prior To The Phase III Trial Of Lenalidomide Versus Observation Alone In Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma (E3A06): A Trial Coordinated By The Eastern Cooperative Oncology Group

Sagar Lonial, M.D., Susanna Jacobus, Matthias Weiss, MD, PhD, Rafael Fonseca, MD, Madhav V. Dhodapkar, MD, S. Vincent Rajkumar, MD

Blood (2013) 122 (21): 3174.

https://doi.org/10.1182/blood.V122.21.3174.3174

Published: 2013

Journal Articles

Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach

Angela Baker, Esteban Braggio, Susanna Jacobus, Sungwon Jung, Dirk Larson, Terry Therneau, Angela Dispenzieri, Scott A. Van Wier, Gregory Ahmann, Joan Levy, Louise Perkins, Seungchan Kim, Kimberly Henderson, David Vesole, S. Vincent Rajkumar, Diane F. Jelinek, John Carpten, Rafael Fonseca

Blood (2013) 121 (16): 3147–3152.

https://doi.org/10.1182/blood-2012-07-443606

Published: 2013

Includes: Supplemental data

Journal Articles

Identification of Significant Barriers to Accrual (BtA) to NCI Sponsored Multiple Myeloma – Clinical Trials (MM-CT): A Step towards Improving Accrual to Clinical Trials.

Blood (2012) 120 (21): 3165.

https://doi.org/10.1182/blood.V120.21.3165.3165

Published: 2012

Journal Articles

Phase II Trial of Initial Safety and Toxicity Prior to the Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma (E3A06): A Trial Coordinated by the Eastern Cooperative Oncology Group

Sagar Lonial, MD, Susanna Jacobus, Matthias Weiss, Rafael Fonseca, MD, Madhav V. Dhodapkar, MD, S. Vincent Rajkumar, MD

Blood (2012) 120 (21): 4079.

https://doi.org/10.1182/blood.V120.21.4079.4079

Published: 2012

Journal Articles

Development of the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM) Scale and Validation in the Eastern Cooperative Oncology Group Trial E1A05,

Matthias Weiss, MD, PhD, Susanna Jacobus, MS, Lynne I Wagner, PhD, David Cella, PhD, Michael S Katz, BS., MBA, Vincent Rajkumar, MD, Rafael Fonseca, MD

Blood (2011) 118 (21): 4184.

https://doi.org/10.1182/blood.V118.21.4184.4184

Published: 2011

Journal Articles

Outcome with Lenalidomide Plus Dexamethasone Followed by Early Autologous Stem Cell Transplantation In the ECOG E4A03 Randomized Clinical Trial

David Samuel diCapua Siegel, MD, PhD, Susanna Jacobus, MS, S. Vincent Rajkumar, MD, Rafat Abonour, MD, Natalie Scott Callander, MD, Michael S Katz, BS., MBA, Rafael Fonseca, David H. Vesole, MD, PhD, On behalf of the Eastern Cooperative Oncology Group

Blood (2010) 116 (21): 38.

https://doi.org/10.1182/blood.V116.21.38.38

Published: 2010

Journal Articles

Oral Antibiotic Prophylaxis of Early Infection In Multiple Myeloma: A URCC/ECOG Phase III Study

David H. Vesole, MD, PhD, Martin M Oken, MD, Charles Heckler, Philip R. Greipp, MD, Michael S Katz, BS., MBA, Susanna Jacobus, MS, Gary R Morrow, PhD, MS, On Behalf of the University of Rochester Cancer Center and the Eastern Cooperative Oncology Group

Blood (2010) 116 (21): 3017.

https://doi.org/10.1182/blood.V116.21.3017.3017

Published: 2010

Journal Articles

Lenalidomide Plus Low-Dose Dexamethasone (Ld): Superior One and Two Year Survival Regardless of Age Compared to Lenalidomide Plus High-Dose Dexamethasone (LD)

David H. Vesole, MD, PhD, Susanna Jacobus, MS, S. Vincent Rajkumar, MD, Rafat Abonour, MD, Natalie Scott Callander, MD, Philip R. Greipp, MD, Rafael Fonseca, Michael S Katz, BS., MBA, David Samuel diCapua Siegel, MD, PhD, On Behalf of the Eastern Cooperative Oncology Group

Blood (2010) 116 (21): 308.

https://doi.org/10.1182/blood.V116.21.308.308

Published: 2010

Journal Articles

Primary Therapy with Bortezomib—the Role of Induction, Maintenance, and Re-Induction in Patients with High Risk Myeloma. Update of Results from E2A02.

Angela Dispenzieri, MD, Susanna Jacobus, Ph.D., David H. Vesole, MD, PhD, S. Vincent Rajkumar, Philip R. Greipp, MD

Blood (2008) 112 (11): 1738.

https://doi.org/10.1182/blood.V112.11.1738.1738

Published: 2008

Journal Articles

Effect of Venous Thrombotic Events on Overall Survival in Multiple Myeloma: Analysis of Thrombotic Events Occurring in E4A03A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma, a Trial Coordinated by the Eastern Cooperative Oncology Group (ECOG).

Susanna Jacobus, Shaji Kumar, Natalie Scott Callander, Rafat Abonour, Rafael Fonseca, David Siegel, Philip Greipp, S. Vincent Rajkumar

Blood (2008) 112 (11): 1740.

https://doi.org/10.1182/blood.V112.11.1740.1740

Published: 2008

Journal Articles

A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group.

S. Vincent Rajkumar, MD, Susanna Jacobus, MS, Natalie Callander, MD, Rafael Fonseca, MD, David Vesole, MD, PhD, Michael Williams, MD, Rafat Abonour, MD, David Siegel, MD, Philip Greipp, MD

Blood (2007) 110 (11): 74.

https://doi.org/10.1182/blood.V110.11.74.74

Published: 2007

Journal Articles

SNP Associations with Event Free Survival in Myeloma from Two Phase III Clinical Trials Using the Bank On A Cure Chip.

Brian G. Van Ness, PhD, John C. Crowley, Ph.D., Christine Ramos, B.S., Suzanne M. Grindle, Ph.D., Antje Hoering, Ph.D., Jeff Haessler, M.S., Susanna Jacobus, M.S., Brian G. Durie, MD, Michael Katz, Ph.D., Vincent S. Rajkumar, MD, Bart Barlogie, MD, David C. Johnson, Ph.D., Gareth J. Morgan, MD

Blood (2006) 108 (11): 131.

https://doi.org/10.1182/blood.V108.11.131.131

Published: 2006

Journal Articles

A Randomized Phase III Trial of Lenalidomide Plus High-Dose Dexamethasone Versus Lenalidomide Plus Low-Dose Dexamethasone in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group.

S. Vincent Rajkumar, MD, Susanna Jacobus, MS, Natalie Callander, MD, Rafael Fonseca, MD, David Vesole, MD, Philip Greipp, MD

Blood (2006) 108 (11): 799.

https://doi.org/10.1182/blood.V108.11.799.799

Published: 2006

NARROW

Outcome with Lenalidomide Plus Dexamethasone Followed By Early Autologous Stem Cell Transplantation in the ECOG-ACRIN E4A03 Randomized Clinical Trial: Long-Term Follow-up

Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma

Phase II Trial Of Initial Safety and Toxicity Prior To The Phase III Trial Of Lenalidomide Versus Observation Alone In Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma (E3A06): A Trial Coordinated By The Eastern Cooperative Oncology Group

Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach

Identification of Significant Barriers to Accrual (BtA) to NCI Sponsored Multiple Myeloma – Clinical Trials (MM-CT): A Step towards Improving Accrual to Clinical Trials.

Phase II Trial of Initial Safety and Toxicity Prior to the Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma (E3A06): A Trial Coordinated by the Eastern Cooperative Oncology Group

Development of the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM) Scale and Validation in the Eastern Cooperative Oncology Group Trial E1A05,

Outcome with Lenalidomide Plus Dexamethasone Followed by Early Autologous Stem Cell Transplantation In the ECOG E4A03 Randomized Clinical Trial

Oral Antibiotic Prophylaxis of Early Infection In Multiple Myeloma: A URCC/ECOG Phase III Study

Lenalidomide Plus Low-Dose Dexamethasone (Ld): Superior One and Two Year Survival Regardless of Age Compared to Lenalidomide Plus High-Dose Dexamethasone (LD)

Primary Therapy with Bortezomib—the Role of Induction, Maintenance, and Re-Induction in Patients with High Risk Myeloma. Update of Results from E2A02.

A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group.

SNP Associations with Event Free Survival in Myeloma from Two Phase III Clinical Trials Using the Bank On A Cure Chip.

A Randomized Phase III Trial of Lenalidomide Plus High-Dose Dexamethasone Versus Lenalidomide Plus Low-Dose Dexamethasone in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only